home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

PPAR Drugs Could Control Cholesterol Levels And Inflammation

 
  January, 5 2001 3:33
your information resource in human molecular genetics
 
     
Three papers in the January issue of Nature Medicine (Vol. 7, Issue 1, 01 Jan 2001) discuss the role of an exciting new receptor that is found in the nucleus of cells called peroxisome proliferator-activated receptors (PPARs) in cholesterol uptake and atherosclerosis.

PPARs are thought to be involved in diseases such as diabetes, obesity, atherosclerosis and cancer. Indeed, rostroglitazone and pioglitazone belong to a class of drugs (thiazolidinediones) that acts on PPAR receptors and has been developed for diabetes. Further understanding of PPAR function could lead to the development of new therapies for all these diseases.

Bart Staels and colleagues from the Pasteur Institute in France show that stimulation of PPAR-gamma and alpha receptors increases the expression of another molecule called ABCA1 that exports cholesterol from cells called macrophages. Exploiting this pathway may be a way to control lipid levels, inflammation and atherosclerosis in the body. Mason Freeman and colleagues at Harvard Medical School also report on the differing effects that stimulating these receptors has on cholesterol movement in and out of macrophages.

In a separate paper, Ronald Evans and colleagues of the Salk Institute for Biological Studies found that the PPAR-gamma receptor is not required for the development of macrophages, and that thiazolidinedione drugs inhibit cytokine production and inflammation in cells that lack PPAR-gamma, suggesting that these drugs target multiple pathways.

Mitch Lazar of the University of Pennsylvania School of Medicine discusses the implications of these findings for cardiovascular diseases in an accompanying News & Views article.

CONTACT:

Dr. Bart Staels
U.325 Inserm
Institut Pasteurde Lille
1 rue Calmete BP245
59019, Lille
France
Tel: +33 3 20 87 73 60
Email: bart.staels@pasteur-lille.fr

Dr. Mason W. Freeman
Lipid Metabolism Unit, GRJ 1328
Massachusetts General Hospital
Harvard Medical School
55 Fruit Street
Boston, MA 02114
USA
Tel: +1 617 726 5906
Email: freeman@frodo.mgh.harvard.edu

Dr. Ronald M. Evans
Howard Hughes Medical Institute
Gene Expression Laboratory
The Salk Institute for Biological Studies
10010 N. Torrey Pines Rd.
La Jolla, CA 92037
USA
Tel: +1 858 453 4100, Ext.1302
Email: evans@salk.edu

Dr. Mitch Lazar
Division of Endocrinology, Diabetes, and Metabolism
University of Pennsylvania School of Medicine
611 CRB
415 Curie Blvd.
Philadelphia, PA 19104
USA
Tel: +1 215 898 0210
Email: Lazar@mail.med.upenn.edu

(C) Nature Medicine press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.